SynthesisEuropean journal of physical and rehabilitation medicine2025
Efficacy of extracorporeal shock wave therapy for post-stroke spasticity and dose-response analysis: a meta-analysis of randomized controlled trials.
Synthesis in European journal of physical and rehabilitation medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPost-stroke spasticity (PSS) is a common complication affecting motor function and quality of life in stroke patients. Extracorporeal shockwave therapy (ESWT) has been proposed as a non-invasive treatment for PSS, though variations in protocols raise questions about its efficacy and optimal dosage. This review aims to evaluate the efficacy of ESWT in reducing PSS and analyze its dose-response relationship. EVIDENCE ACQUISITION: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted. Adults with spasticity following ischemic or hemorrhagic stroke in rehabilitation or hospital-based clinical settings were included. RCTs assessing ESWT versus sham or no intervention were selected, with spasticity reduction measured by the Modified Ashworth Scale (MAS) as the primary outcome. Secondary outcomes included range-of-motion (ROM), functionality, and the Modified Tardieu Scale, assessed in both the short and long term. Risk of bias was evaluated using the revised Cochrane Risk of Bias Tool. Meta-analyses and meta-regression were performed using R software. EVIDENCE SYNTHESIS: Thirteen RCTs with 533 participants were included. Meta-analyses demonstrated that ESWT significantly reduced MAS scores in the short term [mean difference (MD)=-0.85; 95% confidence interval (CI): -1.17 to -0.53, P<0.01] and long term (MD=-0.84; 95% CI: -1.31 to -0.38, P<0.01). Secondary outcomes also improved in both short-term (P<0.01) and long-term analyses (P=0.04). Meta-regression revealed a dose-response relationship for the primary outcome, showing that higher ESWT doses were associated with greater MAS improvement.
conclusionsESWT effectively reduces PSS with short- and long-term benefits. A dose-response relationship suggests higher doses provide better outcomes. However, further research is needed to optimize treatment protocols due to the observed heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.